This Month in Psychopharmacology

Ketamine Transiently Alters Brain Network Dynamics Linked to Rumination and Somatosensory Processing

Ketamine produces rapid antidepressant effects and has been report...

Read More

DT120 Lysergide ODT Receives FDA Breakthrough Therapy Designation for Major Depressive Disorder

Definium Therapeutics announced on September 8, 2026, that the US F...

Read More

Low-Dose Buprenorphine May Enhance Ketamine's Antisuicidal Effects in Major Depression

Suicidal ideation in major depressive disorder (MDD) is a major cli...

Read More

Choosing an Adjunctive Antipsychotic for Major Depressive Disorder

Most patients with major depressive disorder (MDD) do not achieve f...

Read More

Esketamine for Depressed Adolescents at Imminent Suicide Risk

Adolescents with depression have approximately a fivefold increased...

Read More

Exercise Demonstrates Moderate Effects for Depression and Anxiety Across the Lifespan

A recent meta-meta-analysis examining the effects of structured exe...

Read More

Rethinking Mood Disorder Treatment with Immunometabolic Insights

While there are many stimulant and non-stimulant options targeting ...

Read More

Ketogenic Diet Shows Modest Short-Term Benefit in Treatment-Resistant Depression

Studies have suggested that a ketogenic diet –a high-fat, low-carbo...

Read More

Serial Intravenous Ketamine Infusions Not Superior to Usual Inpatient Care for Depression

Serial IV ketamine infusions are increasingly used off-label for tr...

Read More

NRX-101 Development Expanded to Include TMS for Depression

Treatment resistance is common in major depressive disorder, and tr...

Read More

Heart Rate, Cholesterol, and Weight Shifts Vary Widely Across Antidepressant Classes

Antidepressants remain among the most prescribed psychotropics worl...

Read More

FDA Approves Lumateperone as Adjunctive Treatment for Major Depressive Disorder

The FDA has approved lumateperone as an adjunctive therapy with an...

Read More